Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: A comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies

Mycoses

Volumn 57, Issue 11, 2014, Pages 687-698

  Abidi, Maheen Z ^a   Sohail, Muhammad R ^a   Cummins, Nathan ^a   Wilhelm, Mark ^a   Wengenack, Nancy ^a   Brumble, Lisa ^b   Shah, Harshal ^b   Jane Hata, Donna ^b   Mccullough, Ann ^c   Wendel, Amy ^c   Vikram, Holenarasipur R ^c   Kusne, Shimon ^c   Litzow, Mark ^a   Letendre, Louis ^a   Lahr, Brian D ^b   Poeschla, Eric ^a   Walker, Randall C ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Amphotericin B; Combination therapy; Echinocandins; Invasive filamentous fungal infections; Mucormycosis; Outcome

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ABSIDIA; ADULT; ANATOMIC LANDMARK; APOPHYSOMYCES; ARTICLE; BLAKESLEA TRISPORA; CLINICAL ARTICLE; COMPARATIVE STUDY; CUNNINGHAMELLA; DEBRIDEMENT; DISEASE SEVERITY; DRUG BIOAVAILABILITY; FEMALE; GENERAL CONDITION DETERIORATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INVASIVE MUCORMYCOSIS; MALE; MORTALITY; MUCOR; MUCORALES; MUCORMYCOSIS; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; RHIZOMUCOR; RHIZOPUS; SOLID ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL RATE; SYNCEPHALASTRUM; TISSUE INJURY; AGED; CLASSIFICATION; COMBINATION DRUG THERAPY; FUNGUS; GENETICS; HISTORY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FUNGI; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; MUCORMYCOSIS; UNITED STATES; VORICONAZOLE; YOUNG ADULT;

EID: 84907948764     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12222     Document Type: Article

References (34)

1. Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-64.
2. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
3. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199: 1399-406.
4. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11.
5. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
6. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002-11.
7. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
8. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
9. Cuenca-Estrella M, Bernal-Martinez L, Isla G, Gomez-Lopez A, Alcazar-Fuoli L, Buitrago MJ. Incidence of zygomycosis in transplant recipients. Clin Microbiol Infec 2009; 15(Suppl. 5): 37-40.
10. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54(Suppl. 1): S35-43.
11. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl. 1): S23-34.
12. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67.
13. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54: 1629-36.
14. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-6.
15. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-7.
16. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-2.
17. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15(Suppl. 5): 93-97.
18. Xhaard A, Lanternier F, Porcher R et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). Clin Microbiol Infect 2012; 18: E396-400.
19. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-8.
20. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1, 3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
21. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52: 1556-8.
22. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-71.
23. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118: 1216-24.
24. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98: 492-504.
25. Lanternier F, Lortholary O. AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome) [10 mg/kg/j] efficacy against zygomycosis. Med Mal Infect 2008; 38(Suppl. 2): S90-1.
26. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect 2014; 20: 74-81.
27. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis 2012; 54(Suppl. 1): S67-72.
28. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
29. Ibrahim AS, Gebremariam T, Husseiny MI et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008; 52: 1573-6.
30. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010; 54: 1298-304.
31. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51: 1253-8.
32. Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance: focus on mucormycosis. Mycoses 2014; 57: 240-6.
33. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55: 5018-21.
34. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect 2009; 15(Suppl. 5): 2-9.